BRILUMIN Trademark

Trademark Overview

On Monday, March 26, 2012, a trademark application was filed for BRILUMIN with the United States Patent and Trademark Office. The USPTO has given the BRILUMIN trademark a serial number of 79115766. The federal status of this trademark filing is IR CANCELLED - US REGISTRATION CANCELLED as of Saturday, March 26, 2022. This trademark is owned by H. Lundbeck A/S. The BRILUMIN trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparation and substances for the prevention and treatment of disorders and diseases in or affecting the central nervous system; pharmaceutical preparations and substances acting on the central nervous system; central nervous system stimulants; pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological diseases and disorders; pharmaceutical preparations and substances for the prevention and treatment of Alzheimer's disease, depression, psychosis, anxiety, epilepsy, sclerosis, porphyries, Huntington's disease, insomnia, Parkinson disease, schizophrenia, bipolar disorder, oncology, pain, alcoholism and dependency; diagnostic preparations, substances, reagents and agents for medical purposes
brilumin

General Information

Serial Number79115766
Word MarkBRILUMIN
Filing DateMonday, March 26, 2012
Status404 - IR CANCELLED - US REGISTRATION CANCELLED
Status DateSaturday, March 26, 2022
Registration Number4287411
Registration DateTuesday, February 12, 2013
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 27, 2012

Trademark Statements

Goods and ServicesPharmaceutical preparation and substances for the prevention and treatment of disorders and diseases in or affecting the central nervous system; pharmaceutical preparations and substances acting on the central nervous system; central nervous system stimulants; pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological diseases and disorders; pharmaceutical preparations and substances for the prevention and treatment of Alzheimer's disease, depression, psychosis, anxiety, epilepsy, sclerosis, porphyries, Huntington's disease, insomnia, Parkinson disease, schizophrenia, bipolar disorder, oncology, pain, alcoholism and dependency; diagnostic preparations, substances, reagents and agents for medical purposes
Translation of Words in MarkThe wording "BRILUMIN" has no meaning in a foreign language.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, September 13, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameH. Lundbeck A/S
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressDK
Party NameH. Lundbeck A/S
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressDK
Party NameH. Lundbeck A/S
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressDK

Trademark Events

Event DateEvent Description
Monday, October 24, 2022NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Monday, October 24, 2022DEATH OF INTERNATIONAL REGISTRATION
Friday, July 17, 2020TOTAL INVALIDATION PROCESSED BY THE IB
Tuesday, June 16, 2020TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Tuesday, June 16, 2020INVALIDATION PROCESSED
Wednesday, May 13, 2020TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Friday, September 13, 2019CANCELLED SECTION 71
Monday, February 12, 2018COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Thursday, June 12, 2014ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, June 12, 2014TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Saturday, June 8, 2013FINAL DECISION TRANSACTION PROCESSED BY IB
Tuesday, May 21, 2013FINAL DISPOSITION NOTICE SENT TO IB
Tuesday, May 21, 2013FINAL DISPOSITION PROCESSED
Sunday, May 12, 2013FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, February 12, 2013REGISTERED-PRINCIPAL REGISTER
Tuesday, November 27, 2012OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 27, 2012PUBLISHED FOR OPPOSITION
Monday, November 26, 2012NOTIFICATION PROCESSED BY IB
Wednesday, November 7, 2012NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, November 7, 2012NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, November 7, 2012NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, October 25, 2012LAW OFFICE PUBLICATION REVIEW COMPLETED
Monday, October 22, 2012ASSIGNED TO LIE
Tuesday, October 9, 2012APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, October 8, 2012TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, October 8, 2012CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, October 8, 2012TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, September 23, 2012REFUSAL PROCESSED BY IB
Friday, August 31, 2012NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, August 31, 2012REFUSAL PROCESSED BY MPU
Friday, August 31, 2012NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, August 30, 2012NON-FINAL ACTION WRITTEN
Tuesday, August 28, 2012APPLICATION FILING RECEIPT MAILED
Thursday, August 23, 2012ASSIGNED TO EXAMINER
Thursday, August 23, 2012NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, August 20, 2012LIMITATION FROM ORIGINAL APPLICATION ENTERED
Thursday, August 16, 2012SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

brilumin substances pharmaceutical preparations nervous system disease central treatment prevention disorders